Arrow still flies
Written By
During 2016 and 2017 the complex litigation about part of AbbVie's patent portfolio protecting its Humira/adalimumab product drew attention in part because of the granting of a so-called Arrow declaration. Arrow declarations provide a route to commercial certainty for a party seeking to launch or already marketing a product that may be covered by a pending patent application. The declaration is to the effect that the product in question would have been old or obvious at the priority date of a patent application of concern: thus, if the patent application proceeds to grant and were to be asserted against the holder of the declaration, the patent would be found invalid if the product would infringe it. The declaration holder has secured a Gillette defence in advance of any claim for infringement. However, Arrow declarations are not available as of right merely because there is a pending patent application: they are granted only in the Court's discretion after consideration of whether they would serve a useful purpose.
The Humira/adalimumab litigation was the first time that a contested Arrow declaration has found its mark. In the wake of the Courts' various decisions in that litigation, some have questioned whether it is likely that more would be granted in the future. Certainly, the circumstances of the Humira/adalumimab litigation were unusual and would seem unlikely to be repeated. In Mylan v Yeda [2017] EWHC 2629 (Pat) Arnold J refused to grant an Arrow declaration but did make a finding of obviousness which the judge appeared to consider would have the same practical utility between the parties as an Arrow declaration.
GSK clearly were not dissuaded from seeking an Arrow declaration as part of their strategy for their product Ellipta, in respect of which they were already seeking revocation of patents owned by Vectura. However, their claim for an Arrow declaration was struck out in the High Court. HHJ Hacon took the view that there was insufficient basis for granting an Arrow declaration in this case: it was not unusual. GSK appealed.
The Court of Appeal has now confirmed that GSK's claim for an Arrow declaration may proceed to trial in its 28 June 2018 judgment in GSK v Vectura [2018]…
Full article available on PatentHub
Latest insights
More Insights
Balancing the candid disclosure of information to regulators, with the desire to maintain privilege: Recent developments regarding voluntary disclosure agreements
Apr 19 2024
Navigating the legal landscape of plastics – balancing utility with environmental responsibility
Apr 19 2024
